LuciDac 45mg
Original price was: $500.00.$443.24Current price is: $443.24.
LuciDac is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
In Stock
Description
COMPOSITION:
Each film-coated tablet contains Dacomitinib……………………………. 45mg.
INDICATION:
LuciDac is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
DOSAGE AND USE:
Recommended Dosage: 45 mg orally once daily with or without food.
STORAGE:
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING:
Keep medicine out of reach of Children. Do not administer LuciDac during Pregnancy and Lactation.
Reviews
There are no reviews yet.